Vaccine Contract Manufacturing Market Size & Forecast Report, 2014 - 2025

Global Vaccine Contract Manufacturing Market size is expected to reach USD 4.0 billion by 2025, A vaccine provides active acquired immunity to a disease. The demand for vaccine contract manufacturing is increasing in the market. Vaccine manufacturing is a complex process, in which effectivity, safety, and consistency are the most important part for the manufacturers. It offers many services such as production process, cell line development, construction & operation of manufacturing product, process optimization, fermentation, and analytical characterization, which fuels the market growth in the coming years. The vaccine contract manufacturing market registers a CAGR of 9.3% in the upcoming period as the scope, product types, and applications are increasing across the globe.

Vaccine contract services offer cost-saving benefits to their clients. Also, they help to save time in operations & management of a research and production facility. The growing demand for vaccine development from the private sector as well as governments in developing and industrialized countries is expected to witness significant growth of the market in the coming years.

In the market, various types of vaccines are available such as inactivated vaccines, attenuated vaccines, toxoid-based vaccines, subunit-based vaccines, DNA-based vaccines, recombinant vector vaccines, synthetic vaccines, and others. The “attenuated vaccines” are expected to hold a large market share in the upcoming period due to their ability to elicit strong and antibody responses. These vaccines offer lifetime immunities with just one or two doses. Moreover, proper handling conditions, especially concerning storage and maintenance will continue to drive the segment in the coming years.

In addition, in the market some single, as well as combination vaccine, are available. Single vaccines such as influenza virus, ebola virus, chickenpox, smallpox, polio, tetanus, tuberculosis, and others could be explored in the vaccine contract manufacturing industry. The factors that play an important role in the growth of the market include increasing demand, growing population, increasing urbanization & industrialization, growing pharmaceutical industry, increase in the number of countries demanding the introduction of vaccines, stringent government rules & regulations, and increasing awareness about vaccination & its benefits in developing countries. Moreover, the increasing prevalence of various bacterial and viral infections is the main factor driving the growth of the vaccine contract manufacturing market in the next couple of years.

However, the high cost of vaccination, regulatory challenges, and patent expiration in recent times are negatively impacting the growth of the vaccine contract manufacturing industry. The market is widely analyzed based on different regional factors such as gross domestic product (GDP), demographics, acceptance, inflation rate, and others. The market is categorized based on the vaccine type, product type, workflow, application, and geography.

The market is classified into workflow such as downstream and upstream. The “downstream” segment is further segregated into fill & finish operations, packaging, and analytical & QC studies whereas the segment “upstream” is segmented into mammalian expression systems, yeast expression systems, bacterial expression systems, baculovirus/insect expression systems, and others. Vaccine production requires skilled personnel for downstream as well as upstream processing. The “downstream” segment is expected to witness significant growth in the coming years owing to the robust demand for downstream processing and sophisticated equipment for efficient product recovery.

North America is accounting large market share in the years to come owing to the widespread manufacturing of vaccines in this region, coupled with the growing presence of a large number of biopharmaceutical facilities. State and the other laws pertaining to the development of vaccines & other biologics, particularly in Canada and the U.S. are expected to boost the market growth in this region. On the other hand, Asia Pacific is projected to grow at a higher CAGR in the next couple of years due to the growing population, improving infrastructure in several developing countries, and growing pharmaceutical industry.

The key players contributing to the robust development of the vaccine contract manufacturing market include Lonza, Paragon Bioservices Inc., Ajinomoto Althea Inc., FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Merck KGaA, Cytovance Biologics, Catalent Inc., IDT Biologika GmbH, Albany Molecular Research Inc., PRA Health Sciences, ICON plc., Pharmaceutical Product Development, LLC, and Cobra Bio. The major market players are focusing on inorganic growth to sustain themselves amidst fierce competition. As such, mergers, acquisitions, and joint ventures are the need of the hour.

Market Segment:

Vaccine Contract Manufacturing Vaccine Type Outlook (Revenue, USD Million, 2014 - 2025)
    • Attenuated Vaccine
    • Inactivated Vaccine
    • Subunit Vaccines
    • Toxoid Vaccines
    • DNA Vaccines

Vaccine Contract Manufacturing Workflow Outlook (Revenue, USD Million, 2014 - 2025)
    • Downstream
        • Fill & Finish Operations
        • Analytical & QC studies
        • Packaging
    • Upstream
        • Mammalian Expression Systems
        • Bacterial Expression Systems
        • Yeast Expression Systems
        • Baculovirus/Insect Expression Systems
        • Others

Vaccine Contract Manufacturing Application Outlook (Revenue, USD Million, 2014 - 2025)
    • Human Use
    • Veterinary

Vaccine Contract Manufacturing Regional Outlook (Revenue, USD Million, 2014 - 2025)
    • North America
        • U.S.
        • Canada
    • Europe
        • Germany
        • France
    • Asia Pacific
        • India
        • China
    • Latin America
        • Brazil
    • Middle East & Africa
        • South Africa